About iiCON: Infection Innovation Consortium

A global collaborative infectious disease R&D programme, iiCON was established in 2020. Founded with government funding provided through UK Research and Innovation’s flagship Strength in Places Fund, it brings together industry, academia, and the NHS in a concerted effort with a clear aim: to combat the growing global threat posed by infectious diseases and save lives through collaborative innovation.

Led by Liverpool School of Tropical Medicine, our consortium partners Unilever, LifeArc, Liverpool University Hospitals Foundation Trust, University of Liverpool, Evotec, and Infex Therapeutics are working on number of innovative and ambitious programmes across iiCON’s eleven specialist research platforms.

www.infectioninnovation.com or email: iicon@lstmed.ac.uk



Life Sciences

Research

Therapeutics

iiCON: Infection Innovation Consortium

Janet Hemingway

Ruth Cobban

Stephen Gordon

Rasmita Raval

Giancarlo Biagini

Derek Lindsay

The Research and Development (R&D) team at iiCON: Infection Innovation Consortium plays a crucial role in advancing the fight against infectious diseases. Comprising leaders and experts from various disciplines, including long-acting therapeutics, tropical disease biology, experimental medicine, surface science, and biologics discovery, this team drives innovative research initiatives across iiCON's eleven specialized platforms. They work collaboratively to develop new treatments, diagnostic tools, and preventive measures aimed at reducing the global impact of infectious diseases and ultimately saving lives.

Research and Development

��

Research and Development

About

Team members

��������

Research and Development

About

Team members

��